Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages 11127-11132

  Zhang, Guodong ^a,b   Panigrahy, Dipak ^c   Hwang, Sung Hee ^a   Yang, Jun ^a   Mahakian, Lisa M ^d   Wettersten, Hiromi I ^e   Liu, Jun Yan ^a   Wang, Yanru ^a   Ingham, Elizabeth S ^d   Tam, Sarah ^d   Kieran, Mark W ^c,f   Weiss, Robert H ^e,g   Ferrara, Katherine W ^d   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d University of California   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPOXIDE HYDROLASE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LIPID METABOLISM; LOW DRUG DOSE; MALE; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; EPOXIDE HYDROLASES; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL;

EID: 84904990664     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1410432111     Document Type: Article

References (44)

1. Buczynski MW, Dumlao DS, Dennis EA (2009) Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res 50(6):1015-1038.
2. Funk CD (2001) Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294(5548):1871-1875.
3. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276(39):36059-36062.
4. Marnett LJ (2009) The COXIB experience: A look in the rearview mirror. Annu Rev Pharmacol Toxicol 49(1):265-290.
5. Zhang G, Kodani S, Hammock BD (2014) Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res 53(0):108-123.
6. Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8(10):794-805.
7. Schmelzer KR, et al. (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103(37):13646-13651. (Pubitemid 44413961)
8. Liu JY, et al. (2010) Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79(6):880-887.
9. Hwang SH, et al. (2011) Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J Med Chem 54(8):3037-3050.
10. Panigrahy D, et al. (2013) Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci USA 110(33):13528-13533.
11. Panigrahy D, et al. (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122(1):178-191.
12. Zhang G, et al. (2013) Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci USA 110(16): 6530-6535.
13. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181-193.
14. Skrypnyk N, et al. (2014) PPARα activation can help prevent and treat non-small cell lung cancer. Cancer Res 74(2):621-631.
15. O'Reilly MS, et al. (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315-328. (Pubitemid 24324921)
16. Panigrahy D, et al. (2002) PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110(7):923-932.
17. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273-286.
18. Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48(21):6523-6543. (Pubitemid 41504710)
19. Shen HC, Hammock BD (2012) Discovery of inhibitors of soluble epoxide hydrolase: A target with multiple potential therapeutic indications. J Med Chem 55(5): 1789-1808.
20. Adini A, et al. (2009) Matrigel cytometry: A novel method for quantifying angiogenesis in vivo. J Immunol Methods 342(1-2):78-81.
21. Griffioen AW, Molema G (2000) Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52(2):237-268. (Pubitemid 30368433)
22. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676. (Pubitemid 36749215)
23. Koch S, Claesson-Welsh L (2012) Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2(7):a006502.
24. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11(8):558-572.
25. Yang J, Schmelzer K, Georgi K, Hammock BD (2009) Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81(19):8085-8093.
26. Cheng Y, et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567):539-541. (Pubitemid 34408674)
27. Schmelzer KR, et al. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102(28):9772-9777. (Pubitemid 40993644)
28. Node K, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenasederived eicosanoids. Science 285(5431):1276-1279. (Pubitemid 29398616)
29. Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC (2011) EET signaling in cancer. Cancer Metastasis Rev 30(3-4):525-540.
30. Tjin Tham Sjin RM, et al. (2006) Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13(6):619-627.
31. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5(10):2726-2734. (Pubitemid 29493945)
32. Reynolds AR (2009) Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 8(3):253-284.
33. Celik I, et al. (2005) Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65(23):11044-11050. (Pubitemid 41713375)
34. Calabrese EJ, Staudenmayer JW, Stanek EJ (2006) Drug development and hormesis: Changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr Opin Drug Discov Devel 9(1):117-123. (Pubitemid 43099081)
35. Cheranov SY, et al. (2008) An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 111(12):5581-5591.
36. Webler AC, et al. (2008) Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol 295(5): C1292-C1301. (Pubitemid 352790340)
37. Yang S, Wei S, Pozzi A, Capdevila JH (2009) The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch Biochem Biophys 489(1-2):82-91.
38. Wu G, et al. (2006) Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69(2):512-519. (Pubitemid 43098807)
39. Ingber D, et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348(6301):555-557. (Pubitemid 120015110)
40. Udagawa T, et al. (2000) Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. J Pharmacol Exp Ther 294(2):421-427. (Pubitemid 30490811)
41. Aoki S, et al. (2007) Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids. Bioorg Med Chem 15(21): 6758-6762. (Pubitemid 47385240)
42. Antoine N, et al. (1994) AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54(8):2073-2076. (Pubitemid 24138672)
43. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO (2000) Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 97(12):6427-6432. (Pubitemid 30412730)
44. Yeh JR, Mohan R, Crews CM (2000) The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 97(23): 12782-12787.